Cogent Biosciences (COGT)

Executive Summary

Cogent Biosciences is a publicly traded biotechnology company focused on developing precision therapies for genetically driven diseases, with a pipeline centered on bezuclastinib, a potent and selective KIT D816V inhibitor. The company is advancing bezuclastinib across multiple indications, including advanced systemic mastocytosis (AdvSM) and indolent systemic mastocytosis (ISM), where it has shown preliminary efficacy and a favorable safety profile. Additionally, Cogent is exploring bezuclastinib in combination with sunitinib for gastrointestinal stromal tumors (GIST) and has early-stage programs targeting FGFR2/3 (CGT4859) and HER2 (CGT4255), positioning it as a versatile player in targeted oncology.

Upcoming Catalysts (preview)

• Q3 2026Topline data from Phase 2 APEX trial of bezuclastinib in AdvSM (NCT04996875)70% success
• Q4 2026Phase 2 data update for bezuclastinib in ISM (NCT05186753) including patient-reported outcomes60% success
• H2 2026Initial clinical data from Phase 1/2 trial of CGT4859 in FGFR-altered cholangiocarcinoma (NCT06777316)40% success